Additional Monitoring and the Black Triangle: What Marketing Authorisation Holders Must Do

The inverted black triangle in a package leaflet tells patients and healthcare professionals that a medicine is under additional monitoring. For the marketing authorisation holder it is more than a symbol: it changes product information, pharmacovigilance workload and the way safety reporting is encouraged. Knowing why a product is on the list, and when it leaves, avoids avoidable labelling errors.

What additional monitoring is

Under Regulation (EC) No 726/2004, Article 23, the EMA maintains and publishes a list of medicines subject to additional monitoring. The aim is to collect safety information more intensively on products whose profile is less well characterised. Being on the list does not mean a medicine is unsafe. The PRAC reviews the list monthly, and the EMA publishes it.

Which products are included

The mandatory categories include:

  • medicines containing a new active substance that was not authorised in the EU on 1 January 2011;
  • biological medicines authorised after that date;
  • products with a post-authorisation safety study (PASS) requested at or after authorisation;
  • conditional marketing authorisations and authorisations granted under exceptional circumstances;
  • products with an obligation for stricter recording or monitoring of suspected adverse reactions.

Status can be assigned at authorisation or later in the life cycle, for example when a new safety concern emerges. The regulation also allows other products to be added on request, after consulting the PRAC.

Product information requirements

The summary of product characteristics and the package leaflet must carry the black inverted triangle with the statement that the medicine is subject to additional monitoring, followed by a standard sentence encouraging the reporting of suspected adverse reactions. The symbol is specified in Commission Implementing Regulation (EU) No 198/2013. The EMA states that it appears in the product information rather than on the outer packaging.

In practice, problems arise when a variation or renewal is prepared on an older template, or when a product enters or leaves the list and the national leaflet is not updated in step with the EU position.

How long a product stays on the list

Products with a new active substance or a new biological are normally removed five years after the Union reference date, unless the PRAC removes them earlier. For other categories, removal follows once the conditions for inclusion are no longer met. A PASS that has been completed, or a conditional authorisation converted to a standard one, should therefore prompt a check of the product’s status.

Practical points for your pharmacovigilance system

  • Track the monthly list and reconcile it against your portfolio, including nationally authorised products.
  • Link PASS milestones and conditional authorisation obligations to a labelling review.
  • Keep product information templates and translations aligned, so the symbol and statements are consistent across markets.
  • Make reporting routes visible to healthcare professionals and patients, including the national reporting system.

How PQRA helps

PQRA supports marketing authorisation holders in Greece and the EU with pharmacovigilance systems, product information maintenance and post-authorisation lifecycle management. We can audit your portfolio against the additional monitoring list, correct product information and align labelling with your safety commitments.

Contact PQRA to discuss how we can support your products.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *